APP and Alzheimer disease: Nonetheless, the exquisite ability of A2AR blockade to restore the defective A/C CA3 LTP in APP/PS1 mice, in parallel to studies linking A2AR to cognitive deficits11, 12, provides an additional mechanistic support to encourage testing the therapeutic efficacy of A2AR antagonists in early AD patients.